Cargando…

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics

Alzheimer’s disease is biologically heterogeneous, and detailed understanding of the processes involved in patients is critical for development of treatments. CSF contains hundreds of proteins, with concentrations reflecting ongoing (patho)physiological processes. This provides the opportunity to st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tijms, Betty M, Gobom, Johan, Reus, Lianne, Jansen, Iris, Hong, Shengjun, Dobricic, Valerija, Kilpert, Fabian, ten Kate, Mara, Barkhof, Frederik, Tsolaki, Magda, Verhey, Frans R J, Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Molinuevo, José Luís, Engelborghs, Sebastiaan, Bertram, Lars, Lovestone, Simon, Streffer, Johannes, Vos, Stephanie, Bos, Isabelle, Blennow, Kaj, Scheltens, Philip, Teunissen, Charlotte E, Zetterberg, Henrik, Visser, Pieter Jelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805814/ https://www.ncbi.nlm.nih.gov/pubmed/33439986 http://dx.doi.org/10.1093/brain/awaa325

Ejemplares similares

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
por: Tijms, Betty Marije, et al.
Publicado: (2021)

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
por: Konijnenberg, Elles, et al.
Publicado: (2020)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset
por: Hong, Shengjun, et al.
Publicado: (2020)

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics
por: Bos, Isabelle, et al.
Publicado: (2018)

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
por: Stamate, Daniel, et al.
Publicado: (2019)

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
por: Shi, Liu, et al.
Publicado: (2019)

Inflammatory biomarkers in Alzheimer's disease plasma
por: Morgan, Angharad R., et al.
Publicado: (2019)

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study
por: ten Kate, Mara, et al.
Publicado: (2018)

Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset
por: Homann, Jan, et al.
Publicado: (2022)

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort
por: Kim, Min, et al.
Publicado: (2019)

Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort
por: Xu, Jin, et al.
Publicado: (2021)

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology
por: Shi, Liu, et al.
Publicado: (2020)

Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
por: Neumann, Alexander, et al.
Publicado: (2023)

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort
por: Westwood, Sarah, et al.
Publicado: (2020)

Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers
por: Weiner, Sophia, et al.
Publicado: (2022)

Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies
por: Shi, Liu, et al.
Publicado: (2021)

Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
por: Neumann, Alexander, et al.
Publicado: (2022)

Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks
por: Zhang, Yuting, et al.
Publicado: (2022)

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease
por: Skillbäck, Tobias, et al.
Publicado: (2017)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

Harmonization and standardization of biofluid‐based biomarker measurements for AT(N) classification in Alzheimer's disease
por: Giangrande, Chiara, et al.
Publicado: (2023)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
por: Teunissen, Charlotte E., et al.
Publicado: (2018)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
por: Camporesi, Elena, et al.
Publicado: (2021)

Levels of ADAM10 are reduced in Alzheimer’s disease CSF
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2018)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease
por: García-Ayllón, María-Salud, et al.
Publicado: (2017)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Corrigendum to “Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease” [Clin. Mass Spectrom. 14 (Part B) (2019) 74–82]
por: Hansson, Karl, et al.
Publicado: (2022)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)

The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases
por: Reijs, Babette L. R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fminis0m9kogou8q862jdb3lt8